<DOC>
	<DOCNO>NCT00005579</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness dolastatin 10 treat patient indolent lymphoma , Waldenstrom 's macroglobulinemia , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Dolastatin 10 Treating Patients With Indolent Lymphoma , Waldenstrom 's Macroglobulinemia , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Estimate efficacy dolastatin 10 patient indolent lymphoma , Waldenstrom 's macroglobulinemia , chronic lymphocytic leukemia . - Evaluate qualitative quantitative toxicity dolastatin 10 patient population . - Investigate mechanism action dolastatin 10 regard apoptosis effect microtubule . OUTLINE : This open-label , multicenter study . Patients stratified disease ( chronic lymphocytic leukemia v indolent lymphoma v Waldenstrom 's macroglobulinemia ) . All patient receive dolastatin 10 IV bolus every 3 week . Patients continue treatment disease progression , unacceptable toxicity , patient 's withdrawal study . PROJECTED ACCRUAL : A maximum 74 patient accrue study 15 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dolastatin 10</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic diagnosis indolent lymphoma define International Working Formulation category AC diagnosis Waldenstrom 's macroglobulinemia , chronic lymphocytic leukemia Lymphoma must stage III , IV , recurrent ( primary CNS lymphoma lymphomatous meningitis ) Waldenstrom 's macroglobulinemia must least one follow : IGM great 3,000 mg/dL Hemoglobin le 10.0 g/dL Bone marrow involvement great 30 % lymphocyte At least 2 cm lymphadenopathy Serum viscosity great 3.0 Chronic lymphocytic leukemia must intermediate high risk stage IIV progress fludarabine therapy unless patient tolerate fludarabine Intermediate risk group must least one indication active disease : Presence one disease relate B symptom : 10 % loss body weight precede 6 month period , extreme fatigue , fever 100 degree F without evidence infection , night sweat Massive ( great 6 cm leave costal margin ) progressive splenomegaly Massive ( great 10 cm long diameter ) progressive lymphadenopathy Progressive lymphocytosis increase 50 % 2 month period anticipate doubling time le 12 month Evidence progressive marrow failure manifest development worsen anemia and/or thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid therapy Intolerance , relapse , failure follow prior fludarabine allow Measurable evaluable disease No untreated immediate life threaten tumor complication PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics WBC least 4,000/mm^3* Absolute granulocyte count least 1,500/mm^3* Platelet count least 100,000/mm^3* Hemoglobin least 9 g/dL* NOTE : *Unless document bone marrow involvement Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No prior malignancy except adequately treat basal squamous cell skin cancer , carcinoma situ cervix , well differentiate stage IA prostate cancer , cancer patient disease free five year Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior autologous bone marrow stem cell transplantation Chemotherapy : See Disease Characteristics No 2 prior systemic regimen treatment lymphoma No chemotherapy treatment prior malignancy At least 4 week since chemotherapy recover Prior fludarabine therapy allow Endocrine therapy : See Disease Characteristics Radiotherapy : Prior radiotherapy allow ( index lesion within prior radiotherapy field ) Surgery : Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
</DOC>